Pfizer’s Ibrance has met with immense success in metastatic breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust, the company reported late ...
First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials Among the data, Pfizer will ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole ...
Pfizer’s breast cancer drug Ibrance is under increased pressure from rival CDK4/6 inhibitors from Novartis and Eli Lilly thanks to a couple of big clinical slips. And in the wake of those misses, ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® ...
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled alongside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback